Detection rate of prostate cancer following biopsy among the northern Han Chinese population: a single-center retrospective study of 1022 cases

Yong Jia, Lei-Yi Zhu, Yu-Xin Xian, Xiao-Qing Sun, Jian-Gang Gao, Xin-Hong Zhang, Si-Chuan Hou, Chang-Cun Zhang, Zhao-Xu Liu, Yong Jia, Lei-Yi Zhu, Yu-Xin Xian, Xiao-Qing Sun, Jian-Gang Gao, Xin-Hong Zhang, Si-Chuan Hou, Chang-Cun Zhang, Zhao-Xu Liu

Abstract

Background: Prostate cancer is known to have ethnic and regional differences. The study aimed to clinically evaluate the detection rate of prostate cancer on transrectal ultrasonography (TRUS)-guided prostate biopsy and analyze its characteristics among the northern Han Chinese population at a single center.

Methods: Between October 2009 and September 2016, a total of 1027 Chinese men, who had undergone TRUS-guided prostate biopsy at Qingdao Municipal Hospital, were retrospectively analyzed. Prostate biopsies were performed in the case of an abnormally elevated serum PSA level, and/or abnormal digital rectal examination (DRE) findings, and/or suspicious prostatic imaging findings.

Results: Of the 1022 men enrolled in the analysis, 438 patients (42.8%) were diagnosed with prostate adenocarcinoma histologically. When serum PSA levels were divided into five subgroups (less than 4.0, 4.0 to 10.0, 10.0 to 20.0, 20.0 to 100.0, and ≥ 100.0 ng/ml), the detection rates of prostate cancer were 12.4, 15.9, 34.1, 66.2, and 93.8%, respectively. With serum PSA levels of 4.0 to 10.0 ng/ml, the cancer detection rates for a normal DRE and a suspect DRE finding were 13.5 and 58.2%, respectively. Accordingly, the cancer detection rates for a normal imaging and a suspect imaging finding were 13.5 and 58.2%, respectively. Besides, a large proportion of the patients were in the clinically advanced stage.

Conclusions: The present study data reported a relatively higher prostate cancer detection rate of 42.8% and that the majority of the patients presented with clinically advanced prostate cancers within a local clinical urologic practice. An early detection and screening program for prostate cancer is of great need to reduce the burden from this disease among the northern Han Chinese population.

Keywords: DRE; Detection rate; PSA; Prostate cancer; Retrospective study.

Conflict of interest statement

Ethics approval and consent to participate

For experiments involving human subjects, the protocol was approved by the local ethics committee of Qingdao Municipal Hospital and performed in accordance with the ethical standards.

Consent for publication

Not applicable for this section.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–1092. doi: 10.1016/j.eururo.2012.02.054.
    1. Zhang L, Yang BX, Zhang HT, Wang JG, Wang HL, Zhao XJ. Prostate cancer: an emerging threat to the health of aging men in Asia. Asian J Androl. 2011;13:574–578. doi: 10.1038/aja.2010.126.
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. doi: 10.3322/caac.21166.
    1. Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int. 2013;1:47–58. doi: 10.12954/PI.12014.
    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338.
    1. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161. doi: 10.1056/NEJM199104253241702.
    1. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344:1373–1377. doi: 10.1056/NEJM200105033441806.
    1. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, de Kernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152:2037–2042. doi: 10.1016/S0022-5347(17)32300-5.
    1. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–552. doi: 10.1001/jama.1995.03520310046028.
    1. Lee F, Littrup PJ, Torp-Pedersen ST, Mettlin C, McHugh TA, Gray JM, Kumasaka GH, McLeary RD. Prostate cancer: comparison of transrectal US and digital rectal examination for screening. Radiology. 1988;168:389–394. doi: 10.1148/radiology.168.2.3293108.
    1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–137. doi: 10.1016/j.eururo.2013.09.046.
    1. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58-64.
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–1474. doi: 10.1245/s10434-010-0985-4.
    1. Emiliozzi P, Corsetti A, Tassi B, Federico G, Martini M, Pansadoro V. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology. 2003;61:961–966. doi: 10.1016/S0090-4295(02)02551-7.
    1. Abdollah F, Novara G, Briganti A, Scattoni V, Raber M, Roscigno M, Suardi N, Gallina A, Artibani W, Ficarra V, et al. Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate? Urology. 2011;77:921–925. doi: 10.1016/j.urology.2010.08.048.
    1. Takenaka A, Hara R, Ishimura T, Fujii T, Jo Y, Nagai A, Fujisawa M. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008;11:134–138. doi: 10.1038/sj.pcan.4500985.
    1. Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. BJU Int. 2005;95:545–548. doi: 10.1111/j.1464-410X.2005.05336.x.
    1. Yang WJ, Lee DH, Chung BH, Cho JS, Choi YD, Kim SJ, Cho IR, Kim HS, Kim CI, Hong SJ. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. Urology. 2006;67:333–336. doi: 10.1016/j.urology.2005.08.027.
    1. Seo HK, Chung MK, Ryu SB, Lee KH. Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study. Urology. 2007;70:1109–1112. doi: 10.1016/j.urology.2007.07.052.
    1. Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol. 2000;164:393–396. doi: 10.1016/S0022-5347(05)67368-5.
    1. Eskicorapci SY, Baydar DE, Akbal C, Sofikerim M, Gunay M, Ekici S, Ozen H. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol. 2004;45:444–448. doi: 10.1016/j.eururo.2003.11.024.
    1. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol. 2004;171:1089–1092. doi: 10.1097/01.ju.0000112763.74119.d4.
    1. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270:860–864. doi: 10.1001/jama.1993.03510070082041.
    1. Schroder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, section Rotterdam. Eur Urol. 1999;35:539–543. doi: 10.1159/000019894.
    1. Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer. 1997;80:1818–1829. doi: 10.1002/(SICI)1097-0142(19971101)80:9<1818::AID-CNCR21>;2-7.
    1. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Levesque J, Belanger A. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999, 38:83–91.
    1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–2035. doi: 10.1016/S0140-6736(14)60525-0.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa